U.S. markets open in 4 hours 44 minutes
  • S&P Futures

    3,785.00
    -9.00 (-0.24%)
     
  • Dow Futures

    30,249.00
    -61.00 (-0.20%)
     
  • Nasdaq Futures

    11,598.50
    -25.25 (-0.22%)
     
  • Russell 2000 Futures

    1,763.50
    -4.50 (-0.25%)
     
  • Crude Oil

    87.93
    +0.17 (+0.19%)
     
  • Gold

    1,725.00
    +4.20 (+0.24%)
     
  • Silver

    20.58
    +0.03 (+0.15%)
     
  • EUR/USD

    0.9881
    -0.0003 (-0.03%)
     
  • 10-Yr Bond

    3.7590
    0.0000 (0.00%)
     
  • Vix

    28.97
    -0.10 (-0.34%)
     
  • GBP/USD

    1.1295
    -0.0027 (-0.24%)
     
  • USD/JPY

    144.6790
    +0.0690 (+0.05%)
     
  • BTC-USD

    20,161.34
    +9.78 (+0.05%)
     
  • CMC Crypto 200

    458.17
    -0.24 (-0.05%)
     
  • FTSE 100

    7,053.48
    +0.86 (+0.01%)
     
  • Nikkei 225

    27,311.30
    +190.80 (+0.70%)
     

Amneal to Report Second Quarter 2022 Results on August 5, 2022

·2 min read

BRIDGEWATER, N.J., July 08, 2022--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 5, 2022.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

To access the call through a conference line, dial 1 (844) 200-6205 (in the U.S.) or 1 (929) 526-1599 (international callers). The access code for the call is 236256.

A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial 1 (866) 813-9403 (in the U.S.) or +44 (204) 525-0658 (international callers). The access code for the replay is 862075.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220708005055/en/

Contacts

Anthony DiMeo
Head of Investor Relations
Anthony.DiMeo@amneal.com